Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July

Executive Summary

FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated

You may also be interested in...



Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review

Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application

Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review

Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application

Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?

FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials

Related Content

Topics

UsernamePublicRestriction

Register

PS045672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel